Quero-Hernández A, Reyes-Gómez U, Quero-Estrada A, Sánchez-Navarro LM, González Ortiz AM, Matos-Alviso LJ, Soria-Saavedra FM, Reyes-Hernández KL, Alonso-Pérez NC, Candelas-Delgado E, Espinosa-Sotero C

Language: Spanish
References: 14
Page: 28-33
PDF size: 170.41 Kb.

ABSTRACT

The epidemiological trend of hemato-oncological problems in the pediatric population in our country is increasing and represents the second cause of death in children under 5 years of age. Chemotherapy or immunosuppressive treatment affect the natural or acquired immune response in general, also in the expected antibody titers when vaccines are applied. In addition to the intrinsic way in cancer patients and especially in acute leukemia, there is an alteration in the number and function of B and T lymphocyte cells. The recovery of these cells occurs at least 6 to 12 months after treatment, provided that when there is complete remission of the oncological disease. Infectious complications in cancer patients continue to represent the greatest challenge to improve survival curves, especially in developing countries like ours, requiring specific protocols with broad-spectrum antibiotic regimens and other specific measures for the prevention of infectious diseases, especially those that can be prevented by vaccination. This review focuses on pointing out the current immunization guidelines in the immunocompromised pediatric patient.

REFERENCES

1. Rivera LR, Cárdenas CR, Olaya VA, ShalkowKJ, Pérez GM, Amador ZJ, et al. El niño de población abierta con cáncer en México. Consideraciones epidemiológicas. An. Med. 2015; 60(2): 91-9.

2. Ruggiero A, Battista A, Coccia P, Attina G, Riccardi R. How to manage vaccinations in children with cancer. Pediatr Blood Cancer. 2011; 57(7): 1104-8.

3. Shetty AK, Winter MA. Immunization of children receiving immunosupressive therapy for cancer or hematopoitic stem cell transplantation. Ochsner. J. 2012; 12: 228-43

4. Robin C, Beckerich F, Cordonnier C. Immunization in cancer patients: Where we stand. Pharm Res. 2015; 92: 23-30.

5. Saavedra LJ, Carmen G, Catalán P, González F. Niños con cáncer e infección viral respiratoria: epidemiología, diagnóstico y posibles tratamientos. Enfer Infecc Microbios Clinic. 2011; 29(1): 40-51.

6. Quero HA, Álvarez SR, Vargas VM, Ellis IA, Estrada CR. Tratamiento de niños con enfermedad de Hodgkin usando el esquema COP-AVBD. Rev Mex Ped. 2009; 76(4): 165-9.

7. Martínez ML, Dávila OJ, Cajero AA, González PR. Niños con cáncer, neutropenia y fiebre. Estudio de tres años en el Hospital de especialidades Miguel Hidalgo en Aguascalientes. Rev Enfer Infecc Ped. 2008; 21(84): 104-13.

8. Rivera LR, Cárdenas RC, Olaya VA, Shalkow-KJ, Pérez GM, Pérez GO, et al. Morbimortalidad en el niño con cáncer. En niño de población abierta con cáncer en México. Consideraciones epidemiológicas. An Med (Mex). 2015; 60(2): 91-7.

9. Esposito S, Prada E, Lelii M, Castellazi L. Immunization of children with secondary immunodeficiency. Hum Vaccin Immunother. 2015; 11(11): 2564-2570.

10. Arístegui FJ, Corretgert RJ, García MF, Hernández ST, Moraga LF, de Liria CG. El tope de anticuerpos, la memoria inmunológica y la eficacia protectora de la vacuna frente a Haemophilus influenzae tipo b. An Esp Pediatr. 1999; 50: 341-5.

11. Ljungman P. Vaccination of immunocompromised patients. Clin Microbiol Infect. 2012; 18(suppl.5): 93-9.

12. Sierrasesumaga L. Complicaciones de la varicela en el paciente oncológico y en el trasplante de órganos. An Pediatr. 2003; 59(Supl 1): 32-40.

13. Rubin LG, Levin MJ, Ljungman P, Graham D, Avery R, Tomblyn M, et al. 2013 IDSA Clinical Practice Guideline for vaccination of the Immunocompromised Host. Clin Infect Dis. 2014; 58(3): e44-100.

14. Esposito S, Cecinati V, Brescia L. Vaccinations in children with cancer. Vaccine. 2010; 28(19): 3278- 84.